BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32587329)

  • 1. Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
    Yamashita T; Higashi M; Momose S; Adachi A; Watanabe T; Tanaka Y; Tokuhira M; Kizaki M; Tamaru JI
    Sci Rep; 2020 Jun; 10(1):10391. PubMed ID: 32587329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
    de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
    Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.
    Asano N; Suzuki R; Ohshima K; Kagami Y; Ishida F; Yoshino T; Ogawa H; Morishima Y; Nakamura S
    Int J Hematol; 2010 Apr; 91(3):426-35. PubMed ID: 20217288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
    Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
    Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of Mcl-1 in T-cell non-Hodgkin's lymphoma].
    Lin XB; Jiang WQ; Zhong XY; Luo RZ
    Ai Zheng; 2007 Apr; 26(4):435-9. PubMed ID: 17430669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Vu K; Ai W
    Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.
    van Kester MS; Tensen CP; Vermeer MH; Dijkman R; Mulder AA; Szuhai K; Willemze R; van Doorn R
    J Invest Dermatol; 2010 Feb; 130(2):563-75. PubMed ID: 19710685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
    Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
    Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.
    Yim J; Koh J; Kim S; Song SG; Bae JM; Yun H; Sung JY; Kim TM; Park SH; Jeon YK
    Am J Surg Pathol; 2022 Apr; 46(4):486-497. PubMed ID: 34980830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.
    Liu W; Ji X; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Ying Z; Zhang C; Deng L; Wu M; Feng F; Leng X; Sun Y; Du T; Zhu J
    Cancer Med; 2020 Jun; 9(11):3765-3774. PubMed ID: 32281275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
    Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
    Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
    Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
    Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK
    Xiang C; Wu W; Fan M; Wang Z; Feng X; Liu C; Liu J; Liu G; Xia L; Si H; Gu Y; Liu N; Luo D; Wang Y; Ma D; Hu S; Liu H
    Front Immunol; 2023; 14():1132834. PubMed ID: 37388733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma.
    Lyapichev KA; Tang G; Li S; You MJ; Cheng TJ; Miranda RN; Iyer S; Yin CC; Konoplev S; Bueso-Ramos C; Vega F; Medeiros LJ; Xu J
    Hum Pathol; 2021 Feb; 108():22-31. PubMed ID: 33221344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms].
    Liang Q; Ye ZY; Su ZL; Lin HL; Shao CK; Lin SX; Rao HL; Mei KY; Zhao T; Liu YH; Luo DL; Zhu MG; Chen SH; Lin TY
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):291-5. PubMed ID: 20654150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.
    Chen Z; Chai F; Xi Y; Zhang H; Xu Y; Zhang Z; Li S; Tian X
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):267-278. PubMed ID: 34131801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype.
    Ferreira CR; Zhao S; Sahoo MK; Pinsky B; Weber J; Lage LAPC; Pereira J; Zerbini MCN; Natkunam Y
    Hum Pathol; 2018 Oct; 80():138-144. PubMed ID: 29898383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
    Hsi ED; Horwitz SM; Carson KR; Pinter-Brown LC; Rosen ST; Pro B; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Collie AM; Gruver AM; Grzywacz BJ; Turakhia S; Shustov AR; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):193-200. PubMed ID: 28209473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.